OncoZenge AB (publ)

DB:8LY Stock Report

Market Cap: €4.4m

OncoZenge Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:8LY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Apr 25Buy€7,730Stian KildalIndividual20,439€0.38
28 Mar 25Buy€10,933Stian KildalIndividual20,000€0.55

Insider Trading Volume

Insider Buying: 8LY insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 8LY?
Owner TypeNumber of SharesOwnership Percentage
Private Companies260,0002.22%
VC/PE Firms1,170,6079.99%
Institutions1,893,70016.2%
Individual Insiders3,919,86833.5%
General Public4,469,06938.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 21 shareholders own 61.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.9%
Niclas Holmgren
1,277,023€484.6k0%no data
9.99%
Linc AB
1,170,607€444.2k0%0.28%
9.19%
Östersjöstiftelsen, Endowment Arm
1,076,408€408.5k0%0.32%
4.27%
Andreas Ozbek
500,200€189.8k0%no data
4.26%
Avanza Fonder AB
499,266€189.5k0%no data
2.71%
Nordnet AB (publ), Asset Management Arm
317,078€120.3k0%0.02%
2.69%
Stian Kildal
315,439€119.7k14.7%no data
2.56%
Monica Holmgren Bergqvist
300,000€113.8k0%no data
2.52%
Kalle Holmgren
295,000€111.9k0%no data
2.43%
Jimmy Olsson
285,092€108.2k0%no data
2.22%
Svenska Mäklarkontoret Ab
260,000€98.7k0%no data
1.9%
Joacim Friberg Mansolahti
222,222€84.3k0%no data
1.06%
Lisa Knight
124,285€47.2k0%no data
1.05%
Fredrik Agren
123,231€46.8k0%no data
1.01%
Pirkko Tamsen
118,007€44.8k0%no data
0.77%
Kristofer Lundqvist
90,000€34.2k0%no data
0.76%
Niklas Gillback
88,888€33.7k0%no data
0.63%
Nadim Moued
73,931€28.1k0%no data
0.47%
Ana Eggers
54,686€20.8k0%no data
0.44%
Andre Nyvoll
51,864€19.7k0%no data
0.0081%
FCG Fonder AB
948€359.60%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 02:59
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OncoZenge AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin SuleRedeye